Youhe Gao Phones & Addresses
-
Troy, MI
-
Ann Arbor, MI
-
85 Strathmore Rd, Brighton, MA 02135 (617) 277-2427
-
Farmington, CT
-
New York, NY
-
Hartford, CT
-
New Britain, CT
Publications
Us Patents
Method For Pr-39 Peptide Mediated Selective Inhibition Of Lκbα Degradation
View pageUS Patent:
7202212, Apr 10, 2007
Filed:
Mar 18, 2003
Appl. No.:
10/391155
Inventors:
Michael Simons - Chestnut Hill MA, US
Youhe Gao - Brighton MA, US
Youhe Gao - Brighton MA, US
Assignee:
Beth Israel Deaconess Medical Center - Boston MA
International Classification:
C12N 5/00
US Classification:
514 12, 514 2, 514 15, 435 11, 435 4, 435325
Abstract:
The present invention provides both a method and means for regulating IκBα degradation, NFκB activity, and NFκB-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such IκBα and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with IκBα is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of IκBα, a decrease of NFκB activity, and a down-regulation of NFκB-dependent gene expression.
Method For Pr-39 Peptide Regulated Stimulation Of Angiogenesis
View pageUS Patent:
7202217, Apr 10, 2007
Filed:
Mar 26, 1999
Appl. No.:
09/276868
Inventors:
Michael Simons - Chestnut Hill MA, US
Youhe Gao - Brighton MA, US
Youhe Gao - Brighton MA, US
Assignee:
Beth Israel Deacones Medical Center - Boston MA
International Classification:
A61K 38/00
US Classification:
514 16, 514 12, 514 14, 514 15, 530300, 530324, 435 4
Abstract:
The present invention provides both a method and means for regulating angiogenesis within living cells, tissues, and organs in-situ. The regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for direct interaction with the α7 subunit of such proteasomes as one present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with proteasomes is a decrease in the intracellular degradation of active peptides such as HIF-1α and a consequential stimulation of angiogenesis in-situ.
Method For Pr-39 Peptide Mediated Selective Inhibition Of Iκbα Degradation
View pageUS Patent:
7169604, Jan 30, 2007
Filed:
Dec 29, 1999
Appl. No.:
09/474967
Inventors:
Michael Simons - Chestnut Hill MA, US
Youhe Gao - Brighton MA, US
Youhe Gao - Brighton MA, US
Assignee:
Beth Israel Deaconess Medical Center - Boston MA
International Classification:
C12N 5/00
US Classification:
435325, 514 2, 514 12, 514 15
Abstract:
The present invention provides both a method and means for regulating IκBα degradation, NFκB activity, and NFκB-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such IκBα and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with IκBα is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of IκBα, a decrease of NFκB activity, and a down-regulation of NFκB-dependent gene expression.